Bessemer Group
ACOR

Bessemer Group’s Acorda Therapeutics ACOR Stock Holding History

Bessemer Group’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2
Closed -$1K – 1795
2019
Q3 		$1K Hold
2
– – ﹤0.01% 1703
2019
Q2 		$2K Buy
+2
New +$2.46K ﹤0.01% 1593
2014
Q4 		– Sell
-177
Closed -$718K – 1575
2014
Q3 		$718K Hold
177
– – ﹤0.01% 516
2014
Q2 		$714K Hold
177
– – ﹤0.01% 512
2014
Q1 		$803K Hold
177
– – 0.01% 459
2013
Q4 		$618K Hold
177
– – ﹤0.01% 512
2013
Q3 		$724K Buy
+177
New +$762K 0.01% 463

Other funds holding ACOR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Bessemer Group's ACOR Position: Q4 2019 in Review

Bessemer Group sold out of Acorda Therapeutics (ACOR) in Q4 2019, closing a stake of 2 shares — an estimated $1K sold.

Bessemer Group first reported a position in ACOR in Q3 2013 and held it in 7 quarters. The position peaked at $803K in Q1 2014. 121 funds tracked by Wall St. Rank hold ACOR as of Q4 2019.

  • Bessemer Group reported no remaining Acorda Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Bessemer Group sold 2 Acorda Therapeutics shares in Q4 2019, an estimated $1K.
  • Bessemer Group first reported a position in Acorda Therapeutics in Q3 2013 and held it in 7 quarters.
  • Bessemer Group's Acorda Therapeutics position peaked at $803K in Q1 2014.
  • 121 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2019.

Based on Bessemer Group's 13F filing for Q4 2019, filed 4 Feb 2020.